NYSEMKT:PHGE BiomX (PHGE) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free PHGE Stock Alerts $0.36 +0.02 (+6.08%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.33▼$0.3650-Day Range$0.21▼$0.6852-Week Range N/AVolume327,555 shsAverage Volume68,601 shsMarket Capitalization$16.37 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC Filings Get BiomX alerts: Email Address BiomX MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,865.8% Upside$7.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.44) to ($0.36) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.23 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, BiomX has a forecasted upside of 1,865.8% from its current price of $0.36.Amount of Analyst CoverageBiomX has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PHGE. Previous Next 0.0 Dividend Strength Dividend YieldBiomX does not currently pay a dividend.Dividend GrowthBiomX does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHGE. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for BiomX this week, compared to 0 articles on an average week.Search Interest16 people have searched for PHGE on MarketBeat in the last 30 days. MarketBeat Follows6 people have added BiomX to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BiomX insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.21% of the stock of BiomX is held by insiders.Percentage Held by InstitutionsOnly 36.67% of the stock of BiomX is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BiomX are expected to grow in the coming year, from ($0.44) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiomX is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiomX is -0.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomX has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About BiomX Stock (NYSEMKT:PHGE)BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.Read More PHGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHGE Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comBiomX (NYSEMKT:PHGE) Stock Price Up 6.1%March 27, 2024 | globenewswire.comBiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 18, 2024 | globenewswire.comBiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million FinancingMarch 7, 2024 | markets.businessinsider.comBiomX Buy Rating Justified by Merger Synergy, Enhanced Financial Stability, and Promising Clinical TrialsMarch 7, 2024 | markets.businessinsider.comBiomX Acquisition and Clinical Trial Successes Prompt Buy Rating by Analyst Michael HigginsMarch 7, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates the transaction between BiomX Inc. and Adaptive Phage TherapeuticsMarch 6, 2024 | msn.comWhy BiomX Stock Is Surging TodayMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 6, 2024 | investorplace.comWhy Is BiomX (PHGE) Stock Up 147% Today?March 6, 2024 | globenewswire.comBiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million FinancingJanuary 29, 2024 | msn.comNanoViricides reports positive safety results for COVID drug candidateNovember 14, 2023 | msn.comBiomX GAAP EPS of -$0.13 misses by $0.03November 14, 2023 | finance.yahoo.comBiomX Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 26, 2023 | msn.comMustang Bio stock jumps 10% on FDA acceptance of new drug applicationAugust 9, 2023 | msn.comHC Wainwright & Co. Reiterates BiomX (PHGE) Buy RecommendationAugust 9, 2023 | msn.comBiomX GAAP EPS of -$0.12 beats by $0.02July 19, 2023 | uk.finance.yahoo.comPHGE - BiomX Inc.June 2, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings with Respect to the Warrants of BiomX Inc. (PHGE.WS)May 31, 2023 | finance.yahoo.comBiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)May 16, 2023 | msn.comHC Wainwright & Co. Maintains BiomX (PHGE) Buy RecommendationMay 12, 2023 | finance.yahoo.comBiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of DirectorsMay 12, 2023 | msn.comWhy Is BiomX (PHGE) Stock Up 10% Today?May 8, 2023 | finance.yahoo.comBiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023April 27, 2023 | ca.finance.yahoo.comBiomX Inc. (PHGE) Stock Historical Prices & Data - Yahoo FinanceApril 19, 2023 | ca.finance.yahoo.comBiomX Inc. (PHGE-WT)April 9, 2023 | finance.yahoo.comBiomX Inc. (AMEX:PHGE) Q4 2022 Earnings Call TranscriptSee More Headlines Receive PHGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEMKT:PHGE CUSIPN/A CIK1739174 Webwww.biomx.com Phone972 7 23942377FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,865.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-127.82% Return on Assets-56.50% Debt Debt-to-Equity Ratio0.51 Current Ratio2.84 Quick Ratio2.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book0.51Miscellaneous Outstanding Shares45,980,000Free Float44,044,000Market Cap$16.37 million OptionableNot Optionable Beta1.23 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Jonathan Eitan Solomon MBA (Age 47)CEO & Director Comp: $528.57kMs. Marina Wolfson CPA (Age 40)CFO & Secretary Comp: $279.42kDr. Merav Bassan Ph.D. (Age 58)Chief Development Officer Comp: $356.59kProf. Rotem Sorek Ph.D.Scientific FounderDr. Eran Elinav M.D.Ph.D., Scientific FounderDr. Timothy K. Lu M.D. (Age 43)Ph.D., Scientific Founder Ms. Inbal Benjamini-ElranC.H.R.OMr. Assaf Oron (Age 50)Chief Business Officer Comp: $352.04kMore ExecutivesKey CompetitorsPoxelOTCMKTS:PXXLFNeurAxisNASDAQ:NRXSMinerva NeurosciencesNASDAQ:NERVPieris PharmaceuticalsNASDAQ:PIRSTRACON PharmaceuticalsNASDAQ:TCONView All CompetitorsInsidersAssaf OronBought 3,192 shares on 5/22/2023Total: $861.84 ($0.27/share)View All Insider Transactions PHGE Stock Analysis - Frequently Asked Questions Should I buy or sell BiomX stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BiomX in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PHGE shares. View PHGE analyst ratings or view top-rated stocks. What is BiomX's stock price target for 2024? 1 brokerages have issued 12 month price objectives for BiomX's shares. Their PHGE share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,865.8% from the stock's current price. View analysts price targets for PHGE or view top-rated stocks among Wall Street analysts. How have PHGE shares performed in 2024? BiomX's stock was trading at $0.28 at the start of the year. Since then, PHGE stock has increased by 27.2% and is now trading at $0.3561. View the best growth stocks for 2024 here. How were BiomX's earnings last quarter? BiomX Inc. (NYSEMKT:PHGE) issued its quarterly earnings data on Monday, May, 15th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.02. What other stocks do shareholders of BiomX own? Based on aggregate information from My MarketBeat watchlists, some companies that other BiomX investors own include Abiomed (ABMD), Catalent (CTLT), Hologic (HOLX), Merck & Co., Inc. (MRK), Net Element (NETE), Novavax (NVAX), Quanterix (QTRX), ARCA biopharma (ABIO), AbbVie (ABBV) and AudioEye (AEYE). How do I buy shares of BiomX? Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEMKT:PHGE) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing“Cash Frenzy” to Hit Banks on March 20?Stansberry ResearchDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.